Hims & Hers Health, Inc. (NYSE:HIMS) Given Average Rating of “Hold” by Brokerages

Shares of Hims & Hers Health, Inc. (NYSE:HIMS) have been given a consensus recommendation of “Hold” by the seventeen analysts that are presently covering the company, Marketbeat Ratings reports. Four analysts have rated the stock with a sell rating, nine have assigned a hold rating, three have given a buy rating and one has given a strong buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $39.3214.

A number of research analysts recently issued reports on the stock. BTIG Research lowered their target price on shares of Hims & Hers Health from $85.00 to $60.00 and set a “buy” rating on the stock in a research note on Monday, February 2nd. Barclays started coverage on shares of Hims & Hers Health in a research report on Monday, December 8th. They issued an “overweight” rating and a $48.00 price target on the stock. Evercore assumed coverage on Hims & Hers Health in a report on Monday, January 12th. They issued an “in-line” rating and a $33.00 price target for the company. UBS Group set a $32.00 price objective on Hims & Hers Health in a research report on Tuesday, November 4th. Finally, Leerink Partners raised shares of Hims & Hers Health from a “hold” rating to a “strong-buy” rating in a research note on Thursday, December 4th.

Insider Activity at Hims & Hers Health

In related news, insider Deborah M. Autor sold 7,054 shares of Hims & Hers Health stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total transaction of $258,952.34. Following the sale, the insider directly owned 6,175 shares in the company, valued at $226,684.25. This trade represents a 53.32% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Michael Chi sold 13,750 shares of the firm’s stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total transaction of $504,762.50. Following the sale, the chief operating officer directly owned 305,161 shares of the company’s stock, valued at approximately $11,202,460.31. This trade represents a 4.31% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 129,337 shares of company stock worth $4,651,648. Insiders own 13.71% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Quent Capital LLC purchased a new position in Hims & Hers Health during the 3rd quarter valued at about $28,000. Binnacle Investments Inc purchased a new position in shares of Hims & Hers Health in the third quarter worth approximately $28,000. Virtus Advisers LLC bought a new stake in shares of Hims & Hers Health during the 2nd quarter valued at $26,000. Quaker Wealth Management LLC purchased a new stake in Hims & Hers Health in the second quarter worth about $29,000. Finally, Bessemer Group Inc. increased its holdings in Hims & Hers Health by 105.8% in the 2nd quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock worth $30,000 after acquiring an additional 312 shares in the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Stock Up 3.2%

HIMS stock opened at $16.31 on Friday. The company has a market cap of $3.71 billion, a price-to-earnings ratio of 30.21, a PEG ratio of 2.95 and a beta of 2.43. Hims & Hers Health has a 12-month low of $15.63 and a 12-month high of $72.98. The company has a quick ratio of 1.64, a current ratio of 1.88 and a debt-to-equity ratio of 1.67. The company has a 50 day moving average of $30.86 and a two-hundred day moving average of $42.11.

Hims & Hers Health declared that its board has authorized a share repurchase program on Monday, November 17th that permits the company to buyback $250.00 million in shares. This buyback authorization permits the company to buy up to 3% of its shares through open market purchases. Shares buyback programs are generally an indication that the company’s leadership believes its stock is undervalued.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.